Conditions: Colorectal Cancer
Keywords: Colorectal cancer metastatic colorectal adenocarcinoma anti-EGFR antibody
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 199
Healthy volunteers: no

Brief summary:
To assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and chemotherapy.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Everolimus (RAD001)
Intervention descriptions: intervention 1: Everolimus was supplied in 5 mg tablets in blister packs.

Protocol document: